QDEM PHARMACEUTICALS LIMITED
Get an alert when QDEM PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-06-12 (in 1mo)
Last made up 2025-05-29
Watchouts
None on the register
Cash
£3K
0% vs 2023
Net assets
£6M
+13.3% vs 2023
Employees
—
Average over period
Profit before tax
—
Period ending 2024-12-31
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £25,305,000 | £30,311,000 | |
| Operating profit | £753,000 | £909,000 | |
| Profit before tax | — | — | |
| Net profit | £576,000 | £682,000 | |
| Cash | £3,000 | £3,000 | |
| Total assets less current liabilities | £5,145,000 | £5,827,000 | |
| Net assets | £5,145,000 | £5,827,000 | |
| Equity | £5,145,000 | £5,827,000 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 3.0% | 3.0% | |
| Net margin | 2.3% | 2.3% | |
| Return on capital employed | 14.6% | 15.6% | |
| Current ratio | 2.92x | 2.27x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Qdem Pharmaceuticals Limited is a member of the Napp Pharmaceutical Holdings Limited group and is subject to the overall financing arrangements of the group. As such, the Company has received a formal letter of support from the Company's parent undertaking, Napp Pharmaceutical Holdings Limited, guaranteeing continued financial support to enable the Company to meet its liabilities to creditors as they fall due for the period to 31 August 2026. The directors have assessed that Napp Pharmaceutical Holdings Limited has sufficient resources to provide such support notwithstanding the risks and uncertainties disclosed in its consolidated financial statements.”
Significant events
- “The 2024 Voluntary Scheme came into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access ('2019 Voluntary Scheme'). It shall remain in force for a period of five years.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 14 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JAMIESON, Stephen Johan | Director | 2019-02-22 | Sep 1957 | British |
| LEA, Bryan George | Director | 2011-11-09 | Jun 1961 | British |
Show 14 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| TIERCEL SERVICES LIMITED | Corporate Secretary | 2011-11-09 | 2018-06-11 |
| BAKER, Stuart David | Director | 2017-08-08 | 2019-12-31 |
| CLARKE, Robert Alan | Director | 2011-11-09 | 2012-11-07 |
| DAY, Hywel Rhys | Director | 2017-01-01 | 2024-06-04 |
| HOGG, Allison | Director | 2024-06-04 | 2025-09-30 |
| LEITNER, Dietmar | Director | 2011-11-09 | 2014-11-01 |
| LYNCH, Michael Howard | Director | 2011-11-09 | 2012-12-31 |
| MARTÍNEZ, Alberto | Director | 2014-09-15 | 2016-10-11 |
| MATTESSICH, Antony Charles | Director | 2011-11-09 | 2017-07-31 |
| MITCHELL, Christopher Benbow | Director | 2011-11-09 | 2018-04-12 |
| SCHOFIELD, Julian Paul, Dr | Director | 2011-11-09 | 2019-05-31 |
| SHIELS, Sara Elizabeth | Director | 2011-11-09 | 2012-09-28 |
| SILVER, David Alan | Director | 2012-04-26 | 2019-05-03 |
| WIKSTROM, Ake Gunnar | Director | 2018-04-12 | 2019-02-22 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Napp Pharmaceutical Holdings Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 74 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-11-17 | CH01 | officers | Change person director company with change date | |
| 2025-10-14 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-08 | AA | accounts | Accounts with accounts type full | |
| 2025-05-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-02-06 | AD02 | address | Change sail address company with old address new address | |
| 2025-02-05 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-08-27 | AA | accounts | Accounts with accounts type full | |
| 2024-06-20 | AP01 | officers | Appoint person director company with name date | |
| 2024-06-20 | TM01 | officers | Termination director company with name termination date | |
| 2024-06-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-04 | CH01 | officers | Change person director company with change date | |
| 2023-10-16 | AA | accounts | Accounts with accounts type full | |
| 2023-06-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-12-14 | AA | accounts | Accounts with accounts type full | |
| 2022-07-04 | CH01 | officers | Change person director company with change date | |
| 2022-06-22 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-06-22 | AD02 | address | Change sail address company with old address new address | |
| 2022-02-01 | AA | accounts | Accounts with accounts type full | |
| 2021-07-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-01-08 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+19.8%
£25,305,000 £30,311,000
-
Cash
0%
£3,000 £3,000
-
Net assets
+13.3%
£5,145,000 £5,827,000
-
Employees
—
Not reported
-
Operating profit
+20.7%
£753,000 £909,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers